Physician profile
Nayan Patel
NPI 1134578024
$21,536.24
in general payments reported to CMS, 2019-2025
36 companies · $3,041 in 2025
The $3,041 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $114 · 2021: $495 · 2022: $1,696 · 2023: $8,715 · 2024: $7,473 · 2025: $3,041.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $9,262 · Food and Beverage: $8,170 · Travel and Lodging: $1,098 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $500 · Consulting Fee: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $9,262.12 |
| Food and Beverage | $8,169.61 |
| Travel and Lodging | $1,098.25 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $500.00 |
| Consulting Fee | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $10,724.33 | 2023-2025 | Da Vinci Surgical System, Ion |
| Glaxosmithkline, LLC. | $1,323.25 | 2023-2025 | Nucala, Trelegy Ellipta, Arexvy |
| United Therapeutics Corporation | $1,148.77 | 2023-2025 | Tyvaso, Tyvaso, Remodulin |
| Astrazeneca Pharmaceuticals LP | $954.46 | 2022-2025 | Fasenra, Tezspire, Airsupra |
| Actelion Pharmaceuticals US, INC. | $750.17 | 2022-2025 | Uptravi, Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $681.88 | 2021-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Pulmonx Corporation | $573.98 | 2023-2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Inari Medical, INC. | $562.18 | 2022-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Regeneron Healthcare Solutions, INC. | $510.48 | 2023-2025 | Dupixent |
| Jazz Pharmaceuticals INC. | $488.95 | 2021-2022 | |
| La Jolla Pharmaceutical Company | $425.57 | 2022-2025 | Giapreza |
| Bayer Healthcare Pharmaceuticals INC. | $330.85 | 2023-2025 | |
| Insmed, INC. | $316.28 | 2023-2025 | Arikayce, Brinsupri |
| Grifols USA, LLC | $288.61 | 2023-2025 | Prolastin-C Liquid |
| Genzyme Corporation | $283.31 | 2022-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $217.48 | 2023-2025 | Nuzyra |
| Harmony Biosciences LLC | $214.55 | 2022 | |
| Vapotherm INC | $206.40 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $172.98 | 2023-2025 | |
| Haemonetics Corporation | $155.42 | 2023 | Teg6s Hemostasis System |
| Novartis Pharmaceuticals Corporation | $142.81 | 2023-2025 | |
| Baxter Healthcare | $140.97 | 2023-2025 | Hillrom - Life 2000 Ventilation System, Hillrom - Monarch Airway Clearance System |
| Janssen Pharmaceuticals, INC | $125.00 | 2022 | |
| Electromed, INC. | $120.67 | 2024-2025 | Smartvest |
| Abbvie INC. | $113.21 | 2023-2025 | |
| Shionogi INC | $105.14 | 2023-2025 | Fetroja |
| Merck Sharp & Dohme LLC | $77.95 | 2024-2025 | Winrevair |
| Amgen INC. | $67.25 | 2023-2025 | Tezspire |
| Viatris Specialty LLC | $63.19 | 2025 | Yupelri |
| Verona Pharma, INC. | $57.63 | 2025 | Ohtuvayre |
| Mylan Specialty L.P. | $53.15 | 2023-2024 | Yupelri |
| Pfizer INC. | $39.70 | 2025 | |
| Pinnacle Biologics, INC | $31.07 | 2023 | Photofrin |
| Takeda Pharmaceuticals U.S.A., INC. | $30.44 | 2025 | Glassia |
| Philips North America LLC | $19.24 | 2025 | Vest Therapy Und |
| Ambu INC. | $18.92 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nayan Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.